A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
June 1995
in “
International Journal of Gynecology & Obstetrics
”
Studysummary This article compares cabergoline and bromocriptine for treating hyperprolactinemic amenorrhea and reports no specific findings.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
In a study published in 1994, 459 women with hyperprolactinemic amenorrhea were treated with either cabergoline (0.5 to 1.0 mg twice weekly) or bromocriptine (2.5 to 5.0 mg twice daily) for 24 weeks. The study found that cabergoline was more effective and better tolerated than bromocriptine. Stable normoprolactinemia was achieved in 83% of women treated with cabergoline compared to 59% with bromocriptine. Additionally, 72% of women on cabergoline had ovulatory cycles or became pregnant, versus 52% on bromocriptine. Adverse effects were less frequent and severe with cabergoline, leading to a lower discontinuation rate (3% for cabergoline vs. 12% for bromocriptine). The conclusion was that cabergoline is a more effective and better-tolerated treatment option for women with hyperprolactinemic amenorrhea.
